U.S. Sex Cord Gonadal Stromal Tumor Market Size, Share & Forecast 2026–2032
Report Highlights
- ✓Country: United States
- ✓Market: Sex Cord-Gonadal Stromal Tumor Market
- ✓Market Size 2024: USD 285 million
- ✓Market Size 2032: USD 430 million
- ✓CAGR: 5.3%
- ✓Market Definition: Revenue from diagnosis, surgical resection, systemic and hormonal therapy, and molecular testing for sex cord-gonadal stromal tumors in the United States. Covers granulosa cell, Sertoli-Leydig, and thecoma-fibroma histologies.
- ✓Leading Companies: Roche, AstraZeneca, Merck & Co., Thermo Fisher Scientific, Illumina
- ✓Base Year: 2025
- ✓Forecast Period: 2026–2032
Analyst Recommendation — Lock In Biomarker Agreements: Diagnostic and pharmaceutical sponsors should pursue FDA companion diagnostic agreements for FOXL2 testing before the PDUFA VIII commitment letter reaches Congress in January 2027, since early agreements secure label language. Investors should favor CLIA-certified laboratories with NCD 90.2 coverage.
Sex Cord-Gonadal Stromal Tumors in the U.S.: Market Overview
The U.S. market for sex cord-gonadal stromal tumors was valued at USD 285 million in 2024 and spans diagnostics, surgery, systemic therapy and companion testing. Granulosa cell tumors dominate, representing roughly 70 percent of cases, followed by Sertoli-Leydig cell tumors and thecomas. Demand is concentrated in gynecologic oncology centers, where the volume of rare histologies is high enough to justify specialist pathology review.
Policy has shaped the market's current form in two directions. The federal government, through the National Cancer Institute's Surveillance, Epidemiology, and End Results Program and the NRG Oncology cooperative groups, has been the dominant force in defining incidence data and treatment evidence. Private manufacturers have led assay development, drug commercialization, and companion diagnostic deployment, with pharmaceutical firms relying on Orphan Drug Act incentives to justify development costs.
Policy-Driven Growth in U.S. Sex Cord-Gonadal Stromal Tumor Care
The Orphan Drug Act of 1983 grants seven years of market exclusivity to drugs designated for rare conditions, and Section 45C of the Internal Revenue Code provides a 25 percent tax credit on qualified clinical testing costs. These incentives translate into pipeline investment because sponsors can recover development costs in a market where patient numbers are small. The Act's threshold of fewer than 200,000 U.S. patients qualifies sex cord-stromal subtypes, which lets sponsors pursue designation for granulosa cell tumor programs.
PDUFA VII, the user-fee agreement covering fiscal years 2023 through 2027, commits the FDA to review goals of 10 months after filing for standard and 6 months after filing for priority new molecular entities. Faster review shortens the time before a therapy reaches oncologists treating rare ovarian histologies. Medicare National Coverage Determination 90.2 covers next-generation sequencing for beneficiaries with advanced cancer when a qualifying test is used, which expands molecular profiling of granulosa cell tumors and drives assay volume.
Regulatory Barriers and Compliance Costs
Laboratory-developed tests remain governed primarily by the Clinical Laboratory Improvement Amendments of 1988, administered by CMS with the CDC under 42 CFR Part 493. FDA's May 2024 final rule extending device oversight to laboratory-developed tests was vacated by the U.S. District Court for the Eastern District of Texas on March 31, 2025, in American Clinical Laboratory Association v. FDA. Laboratories offering FOXL2 or inhibin testing must therefore maintain CLIA certificates, proficiency testing enrollment, and qualified personnel, with certificates renewed every two years.
Price controls add a second layer. The Inflation Reduction Act of 2022 created the Medicare Drug Price Negotiation Program, administered by CMS, which selects drugs annually and applies negotiated prices first effective in 2026. The ORPHAN Cures Act, enacted in July 2025, broadened the exclusion for orphan-only drugs, but sponsors whose sex cord-stromal therapies carry a second non-orphan indication lose that protection, which raises compliance planning costs for multi-indication programs.
Policy-Created Opportunities in the United States
Medicare National Coverage Determination 90.2 creates demand for next-generation sequencing across advanced gynecologic cancers. Laboratories able to deliver FOXL2 C134W testing, which is present in more than 95 percent of adult granulosa cell tumors, can capture reimbursed volume under CMS coverage rules. Separately, the NIH Office of Rare Diseases Research funds the Rare Diseases Clinical Research Network, whose natural history studies underpin orphan designation applications for sex cord-stromal programs.
CMS's Transitional Coverage for Emerging Technologies pathway, finalized in 2024, provides five years of expedited Medicare coverage for eligible FDA Breakthrough Devices, which benefits biomarker assays for these tumors. Larotrectinib, approved by the FDA in 2018 for NTRK gene fusion-positive solid tumors, shows how biomarker labels open indications for rare histologies, a model sponsors can apply to sex cord-stromal subsets.
Market at a Glance
| Metric | Value |
|---|---|
| Market Size 2024 | USD 285 million |
| Market Size 2032 | USD 430 million |
| Growth Rate (CAGR) | 5.3% |
| Most Critical Decision Factor | Medicare coverage of molecular testing for granulosa cell tumors |
| Largest Region | South (U.S. Census region) |
| Competitive Structure | Consolidated among pharmaceutical firms; fragmented among laboratories |
Leading Market Participants
- Roche
- AstraZeneca
- Merck & Co.
- GSK
- Eli Lilly
- Thermo Fisher Scientific
- Illumina
- Beckman Coulter
- Siemens Healthineers
- Myriad Genetics
Regulatory and Policy Environment
The primary legislation is the Federal Food, Drug, and Cosmetic Act, codified at 21 U.S.C. 301 et seq., which the FDA enforces for drugs and devices, including companion diagnostics requiring premarket approval under 21 CFR Part 814. The Orphan Drug Act (Public Law 97-414) and the Clinical Laboratory Improvement Amendments of 1988 (42 U.S.C. 263a) complete the core framework. Key compliance requirements include investigational new drug submissions under 21 CFR Part 312, informed consent under 21 CFR Part 50, orphan designation requests to the FDA's Office of Orphan Products Development, and CLIA certification for every testing site.
Upcoming changes include the PDUFA VIII commitment letter, which the FDA must transmit to Congress in January 2027 ahead of reauthorization by September 2027. Congress will decide in 2026 and 2027 whether to legislate oversight of laboratory tests following the court vacatur. Compared with regional peers, the U.S. framework is faster but less uniform: the EU's Regulation (EU) 2017/746 on in vitro diagnostic devices, with transition deadlines extended by Regulation (EU) 2024/1860 to between 2027 and 2029, requires conformity assessment for every test, while the EU Orphan Medicinal Products Regulation (EC) No 141/2000 grants ten years of exclusivity against the U.S. seven.
Long-Term Policy Outlook for U.S. Sex Cord-Gonadal Stromal Tumors
The 2027 PDUFA VIII reauthorization will set review goals and user-fee funding through 2032, determining how quickly biomarker-defined labels for these tumors reach the market. Without new legislation, CLIA remains the governing framework for laboratory tests through 2032, and laboratories will continue to build validation data under that regime. Congressional action on laboratory test oversight is the single largest unresolved variable for diagnostic revenue.
CMS revisions to NCD 90.2 and expanded TCET eligibility will shift reimbursement toward molecular profiling of granulosa cell tumors. Annual drug selection caps under the Medicare Drug Price Negotiation Program will rise through the decade, increasing pricing pressure on multi-indication therapies. These changes will push growth toward diagnostics and biomarker-matched therapies, lifting the U.S. market from USD 285 million in 2024 to USD 430 million by 2032 at a 5.3% CAGR.
Frequently Asked Questions
Market Segmentation
- Granulosa Cell Tumors
- Sertoli-Leydig Cell Tumors
- Thecomas and Fibromas
- Sex Cord Tumors with Annular Tubules
- Others
- Surgical Resection
- Platinum-Based Chemotherapy
- Aromatase Inhibitor Therapy
- Targeted and Immunotherapy
- Radiotherapy
- Academic Medical Centers
- Community Hospitals
- Reference Laboratories
- Ambulatory Surgical Centers
Table of Contents
Research Framework and Methodological Approach
Information
Procurement
Information
Analysis
Market Formulation
& Validation
Overview of Our Research Process
MarketsNXT follows a structured, multi-stage research framework designed to ensure accuracy, reliability, and strategic relevance of every published study. Our methodology integrates globally accepted research standards with industry best practices in data collection, modeling, verification, and insight generation.
1. Data Acquisition Strategy
Robust data collection is the foundation of our analytical process. MarketsNXT employs a layered sourcing model.
- Company annual reports & SEC filings
- Industry association publications
- Technical journals & white papers
- Government databases (World Bank, OECD)
- Paid commercial databases
- KOL Interviews (CEOs, Marketing Heads)
- Surveys with industry participants
- Distributor & supplier discussions
- End-user feedback loops
- Questionnaires for gap analysis
Analytical Modeling and Insight Development
After collection, datasets are processed and interpreted using multiple analytical techniques to identify baseline market values, demand patterns, growth drivers, constraints, and opportunity clusters.
2. Market Estimation Techniques
MarketsNXT applies multiple estimation pathways to strengthen forecast accuracy.
Bottom-up Approach
Aggregating granular demand data from country level to derive global figures.
Top-down Approach
Breaking down the parent industry market to identify the target serviceable market.
Supply Chain Anchored Forecasting
MarketsNXT integrates value chain intelligence into its forecasting structure to ensure commercial realism and operational alignment.
Supply-Side Evaluation
Revenue and capacity estimates are developed through company financial reviews, product portfolio mapping, benchmarking of competitive positioning, and commercialization tracking.
3. Market Engineering & Validation
Market engineering involves the triangulation of data from multiple sources to minimize errors.
Extensive gathering of raw data.
Statistical regression & trend analysis.
Cross-verification with experts.
Publication of market study.
Client-Centric Research Delivery
MarketsNXT positions research delivery as a collaborative engagement rather than a static information transfer. Analysts work with clients to clarify objectives, interpret findings, and connect insights to strategic decisions.